Veradermics publishes Study 302 Part B Phase 3 hair loss data presentation
MANE•MANE•MANE•MANE•Veradermics reported 12-month Phase 3 results for VDPHL01 in men with mild-to-moderate pattern hair loss. Non-vellus hair counts rose by 29.7 hairs/cm² with once-daily dosing and 43.9 hairs/cm² with twice-daily dosing; hair coverage improved for 79.8% and 89.1%, respectively.
Veradermics published its Study 302 Part B presentation reporting 12-month results for VDPHL01 in men with mild-to-moderate pattern hair loss. Non-vellus hair counts increased by 29.7 hairs/cm² with 8.5 mg once-daily dosing, versus 43.9 hairs/cm² with twice-daily dosing. Hair coverage improvement was reported by 79.8% of once-daily recipients and 89.1% of twice-daily recipients.
Continued treatment produced no treatment-related serious adverse events or cardiac adverse events of special interest. No adverse-event-related discontinuations occurred in the continued-treatment group during Part B.
